Molecular Classification in Mexican Patients With Endometrial Cancer and Its Impact on Prognosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: David F Cantu-de-León, PhD
- Phone Number: 21016 +52-55-5628-0400
- Email: dfcantu@gmail.com
Study Contact Backup
- Name: Diddier Prada, PhD
- Phone Number: +52-55-41-42-18-02
- Email: pradadiddier@gmail.com
Study Locations
-
-
Cdmx
-
Mexico City, Cdmx, Mexico, 14080
- Recruiting
- Instituto Nacional de Cancerologia
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Criteria: Inclusion Criteria:
- Clinical diagnosis of endometrioid-type endometrial cancer with samples available
- That the patients have undergone surgery at INCan.
Exclusion Criteria:
- Samples with CEE of non-endometroid type.
- Samples from patients with double primary neoplasm, including carcinoma ductal in situ, squamous cell skin cancers, and cervical carcinoma in situ
- History of malignancy < 5 years prior with no evidence of disease (i.e., remission).
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients with EC endometroid
Patients with EC endometroid subtype and peripheral blood, treated during 2015-2019 at the INCan.
|
Patients with EC endometroid
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
sequence the exome
Time Frame: 2024-2025
|
Molecular classification of endometroid-type endometrial cancer in Mexican participants based on POLE and TP53 mutations as well as makers of microsatellite instability (MSH2, MLH1, PMS1, PMS2, MSH6, and MSH3).
|
2024-2025
|
|
Determine POLE mutations
Time Frame: 2024-2025
|
Determine POLE mutations by massive next-generation sequencing of a discovery cohort in patients with endometroid-type EC.
|
2024-2025
|
|
Determine microsatellite instability
Time Frame: 2025-2026
|
To perform validation of POLE mutation by real-time PCR in a validation cohort of patients with endometroid-type EC.
|
2025-2026
|
|
Validation
Time Frame: 2025-2026
|
To perform validation of POLE mutation by real-time PCR in a validation cohort of patients with endometroid-type EC.
|
2025-2026
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival
Time Frame: 2025-2026
|
To describe the overall survival of molecular types of endometroid-type EC in INCan patients.
|
2025-2026
|
|
Disease-free surviva
Time Frame: 2025-2026
|
To describe the disease-free survival of the molecular types of endometroid-type EC in INCan patients.
|
2025-2026
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: David F Cantu-de-León, PhD, The Principal Investigator
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- (023/028/ICI/(CEI/017/23)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.